Shigeo Sato

7.9k total citations · 3 hit papers
71 papers, 6.4k citations indexed

About

Shigeo Sato is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shigeo Sato has authored 71 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 24 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Shigeo Sato's work include RNA Research and Splicing (13 papers), Genomics and Chromatin Dynamics (12 papers) and RNA and protein synthesis mechanisms (9 papers). Shigeo Sato is often cited by papers focused on RNA Research and Splicing (13 papers), Genomics and Chromatin Dynamics (12 papers) and RNA and protein synthesis mechanisms (9 papers). Shigeo Sato collaborates with scholars based in Japan, United States and South Korea. Shigeo Sato's co-authors include Ronald Conaway, Joan Conaway, Chieri Tomomori‐Sato, Naoya Fujita, Takumi Kamura, Takashi Tsuruo, Tari Parmely, Michael P. Washburn, Laurence Florens and Takao Yamori and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Shigeo Sato

71 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex

2000 543 citations Takumi Kamura, Shigeo Sato et al. profile →
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families

1998 507 citations Takumi Kamura, Shigeo Sato et al. Genes & Development profile →
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

2017 329 citations Ken Uchibori, Naohiko Inase et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shigeo Sato Japan	41	4.4k	1.9k	1.0k	638	567	71	6.4k
Domenico Delia Italy	43	4.2k 1.0×	2.5k 1.3×	1.2k 1.2×	950 1.5×	462 0.8×	125	6.9k
Mats Ljungman United States	52	6.1k 1.4×	2.1k 1.1×	1.5k 1.4×	432 0.7×	507 0.9×	155	7.6k
Juan Carlos Lacal Spain	54	5.7k 1.3×	1.8k 0.9×	1.8k 1.8×	660 1.0×	485 0.9×	162	8.4k
Grazia Ambrosini United States	27	4.8k 1.1×	2.2k 1.2×	743 0.7×	1.2k 1.9×	643 1.1×	48	6.8k
Edward V. Prochownik United States	53	6.4k 1.5×	2.1k 1.1×	1.8k 1.7×	902 1.4×	478 0.8×	170	8.6k
Alan P. Fields United States	54	6.1k 1.4×	1.8k 1.0×	1.1k 1.0×	612 1.0×	471 0.8×	120	7.9k
Nancy E. Kohl United States	42	5.2k 1.2×	2.4k 1.2×	843 0.8×	529 0.8×	511 0.9×	97	8.0k
Eugenio Santos Spain	45	5.8k 1.3×	2.2k 1.1×	1.1k 1.1×	802 1.3×	657 1.2×	154	8.3k
Carlo Rago United States	21	5.6k 1.3×	2.3k 1.2×	2.2k 2.1×	635 1.0×	537 0.9×	32	7.6k
Henrik Daub Germany	35	5.4k 1.2×	1.7k 0.9×	524 0.5×	705 1.1×	403 0.7×	56	7.6k

Countries citing papers authored by Shigeo Sato

Since Specialization

Citations

This map shows the geographic impact of Shigeo Sato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigeo Sato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigeo Sato more than expected).

Fields of papers citing papers by Shigeo Sato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shigeo Sato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigeo Sato. The network helps show where Shigeo Sato may publish in the future.

Co-authorship network of co-authors of Shigeo Sato

This figure shows the co-authorship network connecting the top 25 collaborators of Shigeo Sato. A scholar is included among the top collaborators of Shigeo Sato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shigeo Sato. Shigeo Sato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abe, Ryota, Miho Shimada, Tomonori Hirose, et al.. (2022). The 3′ Pol II pausing at replication-dependent histone genes is regulated by Mediator through Cajal bodies’ association with histone locus bodies. Nature Communications. 13(1). 18 indexed citations

Sato, Shigeo, et al.. (2018). CTD-dependent and -independent mechanisms govern co-transcriptional capping of Pol II transcripts. Nature Communications. 9(1). 3392–3392. 20 indexed citations

Uchibori, Ken, Naohiko Inase, Mitsugu Araki, et al.. (2017). Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature Communications. 8(1). 14768–14768. 329 indexed citations breakdown →

Katayama, Ryohei, et al.. (2014). Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance. Molecular Cancer Therapeutics. 13(12). 2978–2990. 52 indexed citations

Matsuo, Junichi, Yoshinori Tsukumo, Sakae Saito, et al.. (2012). Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation. Molecular Cancer Therapeutics. 11(5). 1082–1091. 18 indexed citations

Ono, Naomi, Toshikazu Yamazaki, Yoshito Nakanishi, et al.. (2011). Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers. Cancer Science. 103(2). 342–349. 21 indexed citations

Nakazawa, Youya, Satoshi Takagi, Shigeo Sato, et al.. (2011). Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti‐Aggrus/podoplanin antibodies. Cancer Science. 102(11). 2051–2057. 48 indexed citations

Morishita, Daisuke, Miho Takami, Ryohei Katayama, et al.. (2010). Cell-permeable Carboxyl-terminal p27Kip1 Peptide Exhibits Anti-tumor Activity by Inhibiting Pim-1 Kinase. Journal of Biological Chemistry. 286(4). 2681–2688. 28 indexed citations

Tokuda, Emi, Naoya Fujita, Tomoko Oh‐hara, et al.. (2007). Casein Kinase 2–Interacting Protein-1, a Novel Akt Pleckstrin Homology Domain-Interacting Protein, Down-regulates PI3K/Akt Signaling and Suppresses Tumor Growth In vivo. Cancer Research. 67(20). 9666–9676. 53 indexed citations

10.

Mashima, Tetsuo, Tomoko Oh‐hara, Shigeo Sato, et al.. (2005). p53-Defective Tumors With a Functional Apoptosome-Mediated Pathway: A New Therapeutic Target. JNCI Journal of the National Cancer Institute. 97(10). 765–777. 98 indexed citations

11.

Conaway, Ronald, Shigeo Sato, Chieri Tomomori‐Sato, Tingting Yao, & Joan Conaway. (2005). The mammalian Mediator complex and its role in transcriptional regulation. Trends in Biochemical Sciences. 30(5). 250–255. 226 indexed citations

12.

Tomomori‐Sato, Chieri, Shigeo Sato, Tari Parmely, et al.. (2004). A Mammalian Mediator Subunit that Shares Properties with Saccharomyces cerevisiae Mediator Subunit Cse2. Journal of Biological Chemistry. 279(7). 5846–5851. 23 indexed citations

13.

Cai, Yong, Jingji Jin, Chieri Tomomori‐Sato, et al.. (2003). Identification of New Subunits of the Multiprotein Mammalian TRRAP/TIP60-containing Histone Acetyltransferase Complex. Journal of Biological Chemistry. 278(44). 42733–42736. 185 indexed citations

14.

Sugimoto, Yoshikazu, Satomi Tsukahara, Shigeo Sato, et al.. (2003). Drug‐selected co‐expression of P‐glycoprotein and gp91 in vivo from an MDR1‐bicistronic retrovirus vector Ha‐MDR‐IRES‐gp91. The Journal of Gene Medicine. 5(5). 366–376. 16 indexed citations

15.

Kato, Yukinari, Naoya Fujita, Akiko Kunita, et al.. (2003). Molecular Identification of Aggrus/T1α as a Platelet Aggregation-inducing Factor Expressed in Colorectal Tumors. Journal of Biological Chemistry. 278(51). 51599–51605. 233 indexed citations

16.

Kamura, Takumi, Shigeo Sato, Dewan Haque, et al.. (1998). The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes & Development. 12(24). 3872–3881. 507 indexed citations breakdown →

17.

Shinohara, Tsutomu, Yoshikazu Sugimoto, Shigeo Sato, Saburo Sone, & Takashi Tsuruo. (1997). Combination Therapy with Antibody and Interleukin–2 Gene Transfer against Multidrug–resistant Cancer Cells. Japanese Journal of Cancer Research. 88(11). 1100–1107. 1 indexed citations

18.

Yamori, Takao, et al.. (1997). Anti‐tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts. Japanese Journal of Cancer Research. 88(12). 1205–1210. 58 indexed citations

19.

Tsuruo, Takashi, Shigeo Sato, & Keisuke Yusa. (1989). Antitumor Activity of ME2303, a Fluorine‐containing Anthracycline, against Human Tumors Implanted in Nude Mice. Japanese Journal of Cancer Research. 80(7). 686–689. 4 indexed citations

20.

Orii, Tadao, Kazuko Sukegawa, Shigeo Sato, et al.. (1972). A New Type of Mucolipidosis with β-Galactosidase Deficiency and Glycopeptiduria. The Tohoku Journal of Experimental Medicine. 107(4). 303–315. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact